Yahong Pharmaceutical (688176.SH) disclosed its 2023 annual report. The company achieved operating income of 13 during the reporting period...
According to the Zhitong Finance App, Yahong Pharmaceutical (688176.SH) disclosed its 2023 annual report. The company achieved revenue of 13.7533 million yuan during the reporting period, an increase of 52,604.25% over the previous year. The net loss attributable to shareholders of listed companies was 400 million yuan, and the net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss was 432 million yuan. The loss increased year-on-year.
During the reporting period, the company's revenue increased compared to the same period last year. The main reason was that the company expanded its sales team size and began selling prazopanib tablets (trade name: Depite) and neratinib maleate tablets (trade name: OUBI) in the fourth quarter of 2023), while 2022 revenue was mainly due to the low revenue base of APL-1706 and disposable cystoscopy products (APLD-2101) declared and realized as clinically urgently needed imported drugs and medical devices in the Lecheng International Medical Tourism Pilot Zone in Boao, Hainan. The company's core products are all under development, and commercial products have not been sold on a large scale.